Develops nanoviricide drugs for viral diseases.
Jun 2026Revenue $0.00/yrExpenses $8.31M/yr
No trendCash runway ≈ 4 months from Jun 2026
Figures by year
When will Nanoviricides be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $0.00 and expenses $8.31M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Jun 2026 | $0.00 | $8.31M | −$8.31M |
| Jun 2025 | $0.00 | $9.59M | −$9.59M |
| Jun 2024 | $0.00 | $8.52M | −$8.52M |
| Jun 2023 | $0.00 | $8.94M | −$8.94M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.